Medtronic announced several regulatory milestones for its Hugo robotic-assisted surgery platform, including FDA submissions for general and gynecologic surgery indications and the LigaSure™ RAS instrument, alongside FDA clearance for its ProGrip™ Advanced hernia mesh. The developments expand the company’s robotic surgery portfolio and support its growth strategy in minimally invasive surgical care.
Medtronic reported robust fiscal 2026 results, fueled by strong growth in cardiovascular, medical surgical, and diabetes technologies, while advancing key product launches, regulatory milestones, and strategic acquisitions.
Boston Scientific will invest $138 million to build a 500,000-square-foot global medical device distribution facility in Plainfield, Indiana, creating up to 300 high-wage jobs and expanding the state’s growing life sciences sector.
The most recent AI thought leadership published on MedTechIntelligence.com.
Market Access is now the central input into M&A and value-driven divestitures, enabling MedTech leaders to reshape portfolios for strategic advantage, long-term growth, and greater value to patients – unlocking their full potential.
Boston Children’s Hospital physicians say one of the greatest risks in pediatric ICUs is delayed de-escalation of care, which can expose children to prolonged ventilation, sedation, and vasoactive medications. They argue that AI-driven clinical intelligence can help clinicians identify safer timing for weaning and extubation, supporting recovery and improving long-term outcomes.
Artivion has finalized its acquisition of Endospan Ltd., adding the FDA-approved NEXUS Aortic Arch System to its portfolio of aortic arch therapies. The deal strengthens the company’s position in the growing endovascular aortic repair market and adds a pipeline of next-generation arch technologies.
Tecomet and Orchid Orthopedic Solutions have completed a merger to create a larger global contract manufacturing platform serving MedTech and Aerospace & Defense customers with expanded capabilities and supply chain reach.
Up to 1,000 jobs globally could be cut over the next three years as part of a major restructuring effort following weaker first-half earnings driven by declining sales, currency pressures, and weak market demand.
Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions and solidifies Natera’s Treatment on MRD (TOMR) approach for MIBC care.
